Texas THC Legal Battle: Hemp vs. Medical Cannabis Licensing Wars

Executive Summary

Texas cannabis companies are locked in an escalating legal battle over which businesses can legally sell THC products in the state, creating a complex regulatory turf war that threatens to reshape the state's emerging cannabis market. The conflict centers on competing interpretations of state law governing hemp-derived THC products versus medical cannabis dispensaries, with millions of dollars in market share at stake. Licensed medical cannabis operators argue that only they possess the legal authority to sell THC products under the Texas Compassionate Use Program, while hemp retailers contend that the 2018 Farm Bill and subsequent Texas legislation permit them to sell products derived from hemp containing delta-8 THC, delta-9 THC, and other cannabinoids. The dispute has drawn in state regulators, industry trade groups, and lawmakers, with potential implications for patient access, tax revenue, and the future of cannabis policy in the nation's second-largest state. As Texas courts and the Department of State Health Services navigate this regulatory gray area, the outcome will determine whether Texas follows a tightly controlled medical model or allows a more open hemp-derived market to flourish.

Why This Matters

The Texas THC legal battle affects patient access for over 29 million residents, determines the fate of hundreds of businesses, and could influence cannabis policy across conservative-leaning states nationwide. Texas operates one of the most restrictive medical cannabis programs in the United States, with the Compassionate Use Program serving approximately 75,000 registered patients as of September 2026. These patients rely on low-THC cannabis products for conditions including epilepsy, PTSD, cancer, and autism.

The financial stakes are substantial. The Texas hemp-derived cannabinoid market generated an estimated $500 million in sales during 2025, according to industry analysts, while the state's licensed medical cannabis dispensaries reported approximately $180 million in revenue. Licensed dispensaries have invested tens of millions of dollars in cultivation facilities, processing equipment, and compliance infrastructure based on the expectation of regulatory exclusivity.

For consumers and patients, the legal uncertainty creates confusion about product safety, testing standards, and legal risk. Hemp-derived products sold in convenience stores and smoke shops typically undergo less rigorous testing than medical cannabis products, raising concerns among physicians and patient advocates about quality control and accurate labeling. The Texas Medical Association has called for clearer regulatory oversight of all THC products to ensure patient safety.

The battle also carries implications for state tax revenue and local economic development. Licensed medical cannabis operators pay significant licensing fees and taxes, while hemp retailers operate under less stringent financial obligations. Cities and counties across Texas are watching closely, as the outcome will determine zoning authority and local tax opportunities.

Background and History

Texas's cannabis legal framework evolved through a series of incremental legislative changes that created overlapping and sometimes contradictory authorities for different types of THC products.

The Compassionate Use Act (2015)

Texas first authorized limited medical cannabis in 2015 when the legislature passed the Compassionate Use Act, signed by Governor Greg Abbott. The original law, codified in Texas Health and Safety Code Chapter 169, permitted only patients with intractable epilepsy to access low-THC cannabis containing no more than 0.5% THC by weight. The law created a closed-loop system requiring vertical integration, with only three licenses initially awarded to cultivate, process, and dispense medical cannabis.

The Department of State Health Services received regulatory authority to oversee the program, establishing the Compassionate Use Registry of Texas (CURT) to track patients and physicians. The restrictive nature of the program meant that fewer than 1,000 patients enrolled during the first two years of operation.

2019 Expansion (House Bill 3703)

In 2019, the Texas Legislature expanded the Compassionate Use Program through House Bill 3703. The legislation increased the THC cap from 0.5% to 1.0% and added qualifying conditions including terminal cancer, autism, and multiple sclerosis. The expansion increased patient enrollment to approximately 15,000 by the end of 2020, though Texas remained among the most restrictive medical cannabis states.

Federal Farm Bill and Hemp Legalization (2018-2019)

The 2018 Farm Bill removed hemp—defined as cannabis containing less than 0.3% delta-9 THC by dry weight—from the Controlled Substances Act. In response, Texas passed House Bill 1325 in 2019, establishing a state hemp program under the Texas Department of Agriculture. The law legalized hemp cultivation and authorized the manufacture and sale of hemp-derived products, including consumable hemp products.

The legislation created an unintended regulatory gap. While the law clearly legalized hemp and hemp extracts, it did not explicitly address synthesized or concentrated cannabinoids derived from hemp, such as delta-8 THC. Entrepreneurs quickly identified this loophole, and by 2020, hemp-derived delta-8 THC products appeared in smoke shops, gas stations, and online retailers across Texas.

2021 Medical Cannabis Expansion (House Bill 1535)

The 2021 legislative session brought significant expansion to the Compassionate Use Program. House Bill 1535, effective September 1, 2021, raised the THC cap to 5% and added PTSD and all forms of cancer to the qualifying conditions list. The Department of State Health Services also expanded the number of dispensing organizations from three to twelve, creating new market opportunities for licensed operators.

Licensed dispensaries invested heavily in cultivation facilities, with some operators spending $20 million to $40 million on infrastructure. These businesses operated under strict regulatory oversight, including seed-to-sale tracking, mandatory testing for potency and contaminants, and extensive security requirements.

Delta-8 THC Controversy (2021-2023)

In October 2021, the Department of State Health Services attempted to ban delta-8 THC by adding it to the state's controlled substances schedule. The agency argued that delta-8 THC, while derived from legal hemp, was a synthesized tetrahydrocannabinol and therefore prohibited under Texas Health and Safety Code Section 481.103.

Hemp industry groups immediately challenged the rule. In January 2022, Travis County District Judge Jan Soifer issued a temporary injunction blocking the ban, finding that the Department of State Health Services likely exceeded its statutory authority. The judge noted that the 2019 hemp law appeared to legalize all hemp derivatives, and the agency could not unilaterally criminalize a product the legislature had authorized.

The legal battle continued through 2022 and 2023, with the Department of State Health Services appealing the decision. In May 2023, the Third Court of Appeals upheld the injunction, ruling that delta-8 THC derived from legal hemp did not meet the statutory definition of a controlled substance under Texas law. The court found that the legislature, not administrative agencies, must determine which substances are illegal.

2023 Legislative Session and Regulatory Stalemate

During the 2023 legislative session, multiple bills attempted to clarify the legal status of hemp-derived cannabinoids. House Bill 2593 would have explicitly banned delta-8 THC and other intoxicating hemp derivatives, while Senate Bill 1008 proposed a regulatory framework for testing and labeling hemp products. Neither bill advanced out of committee, leaving the regulatory framework unresolved.

Licensed medical cannabis dispensaries grew increasingly frustrated as hemp retailers expanded their market presence without the compliance costs and restrictions imposed on Compassionate Use Program operators. By mid-2024, hemp-derived THC products were available in an estimated 3,000 retail locations across Texas, compared to just twelve licensed medical cannabis dispensaries.

2025 Developments and Escalating Tensions

Throughout 2025, the conflict intensified. The Texas Cannabis Industry Association, representing licensed medical dispensaries, filed a petition with the Department of State Health Services requesting emergency rulemaking to clarify that only licensed operators could sell products containing any amount of THC. The petition argued that allowing unlicensed hemp retailers to sell intoxicating cannabinoids undermined the carefully constructed Compassionate Use Program and created public safety risks.

Simultaneously, the Texas Hemp Coalition, representing hemp farmers and retailers, pushed back against any restrictions. The coalition argued that the 2018 Farm Bill and Texas hemp law clearly authorized all hemp derivatives, and that licensed dispensaries were attempting to use regulatory capture to eliminate market competition.

In November 2025, the Department of State Health Services issued an advisory opinion stating that products containing more than 0.3% delta-9 THC could only be sold by licensed Compassionate Use Program dispensaries, regardless of whether the products were derived from hemp or marijuana. The advisory opinion lacked the force of law but signaled the agency's interpretation of existing statutes.

Current Legal Battle (2026)

The conflict reached a critical point in 2026. In March, a coalition of licensed medical cannabis dispensaries filed suit in Travis County District Court against several hemp retailers, alleging unfair competition and seeking an injunction to prevent the sale of intoxicating hemp-derived products outside the Compassionate Use Program. The lawsuit names both individual retailers and industry trade groups as defendants.

The plaintiffs argue that Texas Health and Safety Code Section 169.001 grants exclusive authority to licensed dispensing organizations to provide cannabis products to qualified patients, and that hemp retailers are violating this statutory scheme by selling products that produce intoxication comparable to marijuana. The complaint cites laboratory testing showing that some hemp-derived products contain total THC levels exceeding 10%, far above the 0.3% delta-9 THC threshold in federal hemp law.

Hemp retailers countered with their own lawsuit in May 2026, seeking a declaratory judgment that their products are legal under both federal and state law. The defendants argue that the Compassionate Use Act regulates "low-THC cannabis" and "medical cannabis," not hemp, and that the legislature deliberately chose to legalize hemp and its derivatives in 2019. They contend that licensed dispensaries are attempting to create a monopoly that the legislature never intended.

As of September 2026, both cases are proceeding through discovery, with trial dates expected in early 2027. The Texas Attorney General's office has filed amicus briefs supporting the position that only licensed dispensaries may sell intoxicating cannabis products, while agricultural interests and libertarian advocacy groups have filed briefs supporting hemp retailers.

Key Players

Department of State Health Services (DSHS)

The Department of State Health Services serves as the primary regulatory authority for Texas's Compassionate Use Program and has taken an increasingly restrictive stance on hemp-derived THC products. The agency oversees licensing for medical cannabis dispensaries, maintains the Compassionate Use Registry, and enforces compliance with testing and labeling requirements. Commissioner Jennifer Shuford has stated publicly that the agency interprets existing law to prohibit the sale of intoxicating hemp products outside the licensed medical program, though the agency lacks clear enforcement authority to shut down hemp retailers without legislative action.

Texas Department of Agriculture (TDA)

The Texas Department of Agriculture regulates hemp cultivation and processing under the state's hemp plan approved by the USDA. Commissioner Sid Miller has been a vocal supporter of hemp farmers and has criticized attempts to restrict hemp-derived products. The agency has licensed over 2,000 hemp growers and processors since 2019, creating a significant agricultural constituency with economic interest in maintaining broad hemp legalization. The TDA has largely stayed out of the retail sales controversy, focusing on agricultural production rather than consumer products.

Licensed Medical Cannabis Dispensaries

Twelve licensed dispensing organizations operate in Texas under the Compassionate Use Program, including Compassionate Cultivation, Goodblend Texas, and Texas Original Compassionate Cultivation. These vertically integrated operators have invested heavily in cultivation facilities, processing labs, and retail locations. They argue that they alone possess the legal authority to sell THC products and that hemp retailers are undercutting their business while avoiding the compliance costs and restrictions that licensed operators face. Several dispensaries have reported revenue declines of 20% to 30% since 2024 as hemp-derived products captured market share.

Texas Cannabis Industry Association

The Texas Cannabis Industry Association represents licensed medical cannabis operators and has been the primary advocacy voice calling for restrictions on hemp-derived THC products. The association has lobbied the legislature for clarifying amendments, filed regulatory petitions with DSHS, and supported litigation against hemp retailers. Executive Director Sarah Martinez has argued that patient safety requires strict regulatory oversight and that the current patchwork system creates unacceptable risks for consumers.

Texas Hemp Coalition

The Texas Hemp Coalition represents hemp farmers, processors, and retailers across the state. The organization has defended the legality of hemp-derived cannabinoids and opposed efforts to restrict sales. The coalition argues that hemp legalization was a deliberate policy choice by both Congress and the Texas Legislature, and that attempts to re-criminalize hemp derivatives contradict legislative intent. The organization has coordinated legal defense efforts for retailers facing lawsuits and regulatory challenges.

Hemp Retailers and Manufacturers

Thousands of small businesses across Texas sell hemp-derived THC products, ranging from dedicated CBD shops to convenience stores and smoke shops. Major retailers include chains like Hometown Hero CBD and independent operators. These businesses typically operate with minimal regulatory oversight compared to licensed dispensaries, though many have voluntarily adopted testing and labeling standards. The industry generates hundreds of millions in annual revenue and employs thousands of Texans.

Patient and Advocacy Groups

Organizations like Texas NORML and the Epilepsy Foundation of Texas have advocated for expanded patient access while expressing concerns about product safety and quality control. Patient advocates generally support broader legalization but want to ensure that all THC products meet consistent testing and labeling standards. Some patient groups have sided with licensed dispensaries, arguing that the medical program provides superior quality control, while others support maintaining access to affordable hemp-derived alternatives.

Legal and Regulatory Framework

The Texas THC legal battle turns on competing interpretations of overlapping federal and state statutes that create ambiguity about which products are legal and who may sell them.

Federal Law: The 2018 Farm Bill

The Agriculture Improvement Act of 2018, commonly known as the Farm Bill, removed hemp from Schedule I of the Controlled Substances Act. The law defines hemp as cannabis containing no more than 0.3% delta-9 THC on a dry weight basis. Section 297A of the Farm Bill, codified at 7 U.S.C. § 1639o, explicitly states that hemp is not a controlled substance and that no federal law prohibits the interstate commerce of hemp or hemp-derived products.

However, the Farm Bill does not address cannabinoids synthesized or concentrated from hemp, creating a regulatory gap that states have interpreted differently. The DEA has issued guidance suggesting that synthetically derived THC remains a controlled substance under 21 U.S.C. § 812, but this interpretation has been challenged in multiple jurisdictions.

Texas Health and Safety Code Chapter 169 (Compassionate Use Program)

Texas Health and Safety Code Chapter 169 establishes the Compassionate Use Program for low-THC cannabis. Section 169.001 defines "low-THC cannabis" as cannabis containing no more than 5% THC by weight and at least 10% CBD. The statute grants exclusive authority to licensed dispensing organizations to cultivate, process, and dispense low-THC cannabis to qualified patients.

Section 169.003 requires that dispensing organizations be licensed by DSHS and meet extensive security, testing, and operational requirements. The statute creates a closed-loop system with strict vertical integration requirements, meaning that licensed operators must control the entire supply chain from cultivation to retail sale.

Licensed dispensaries argue that this statutory scheme implicitly prohibits any other entity from selling cannabis products containing THC, regardless of whether those products are derived from hemp or marijuana. They point to Section 169.002, which states that the chapter applies to "the medical use of low-THC cannabis by a qualified patient," as evidence of legislative intent to channel all THC sales through the licensed program.

Texas Agriculture Code Chapter 121 (Hemp Program)

Texas Agriculture Code Chapter 121, enacted in 2019, establishes the state's hemp program. Section 121.001 defines hemp using the federal definition: cannabis containing no more than 0.3% delta-9 THC on a dry weight basis. Section 121.004 explicitly states that hemp is not a controlled substance under Texas law and that no state law prohibits the manufacture, possession, or sale of hemp or hemp products.

Hemp retailers argue that this statute clearly legalizes all hemp derivatives, including concentrated cannabinoids like delta-8 THC and delta-9 THC products that remain below the 0.3% threshold by weight. They contend that the legislature knew how to prohibit specific substances when it wanted to—as evidenced by the detailed controlled substances schedules in the Health and Safety Code—and chose not to ban hemp-derived cannabinoids.

Texas Controlled Substances Act

Texas Health and Safety Code Chapter 481 establishes the state's controlled substances schedules. Section 481.103 lists tetrahydrocannabinols in Penalty Group 2, making them illegal to manufacture, deliver, or possess without authorization. However, the statute contains exceptions for hemp as defined in Section 121.001 of the Agriculture Code.

The critical legal question is whether hemp-derived cannabinoids fall within the hemp exception or constitute prohibited tetrahydrocannabinols. DSHS has argued that concentrated or synthesized cannabinoids are not "hemp" even if derived from legal hemp plants, while hemp advocates contend that any product derived from legal hemp is itself legal under both federal and state law.

Regulatory Guidance and Administrative Interpretations

DSHS has issued multiple advisory opinions and guidance documents attempting to clarify the legal landscape. The November 2025 advisory opinion stated that products containing more than 0.3% total THC (including delta-8, delta-9, and other isomers) may only be sold by licensed Compassionate Use Program dispensaries. However, this guidance lacks the force of law and has not been adopted through formal rulemaking procedures under the Texas Administrative Procedure Act.

The Texas Department of Agriculture has taken a contrary position, issuing guidance in 2024 stating that all hemp derivatives are legal under state law as long as the source material meets the hemp definition. This conflict between state agencies has contributed to regulatory uncertainty and inconsistent enforcement.

Case Law and Judicial Interpretations

The 2023 Third Court of Appeals decision in Hometown Hero v. Texas Department of State Health Services established important precedent. The court held that DSHS exceeded its statutory authority by attempting to ban delta-8 THC through administrative rulemaking, finding that the legislature must make the policy determination about which substances are controlled. The court emphasized that hemp and its derivatives were explicitly legalized by the 2019 hemp law, and administrative agencies cannot reverse legislative policy choices.

However, that decision addressed only the narrow question of whether DSHS could administratively schedule delta-8 THC. The current litigation raises different questions about whether the Compassionate Use Act creates exclusive sales authority for licensed dispensaries and whether hemp-derived products that produce intoxication comparable to marijuana fall outside the hemp exception.

State-by-State Comparison

Texas's regulatory confusion mirrors similar conflicts in other states, though approaches vary widely based on legislative frameworks and enforcement priorities.

Texas

Texas operates a restrictive medical cannabis program serving approximately 75,000 patients with twelve licensed dispensaries, while simultaneously allowing a largely unregulated hemp-derived THC market with thousands of retail locations. The state has not explicitly banned delta-8 THC or other hemp-derived intoxicating cannabinoids, creating a legal gray area. Possession limits under the Compassionate Use Program allow patients to obtain up to a 90-day supply as prescribed by a physician, with no specific weight limit. Hemp-derived products face no possession limits under current law.

California

California operates a comprehensive adult-use cannabis market alongside a medical program, with clear regulatory authority over all THC products regardless of source. The state's Department of Cannabis Control has asserted jurisdiction over hemp-derived intoxicating products, requiring that any product intended for human consumption containing detectable THC be sold only through licensed cannabis retailers. This approach has largely eliminated the regulatory arbitrage seen in Texas, though enforcement remains challenging given California's vast illicit market.

Colorado

Colorado, the first state to legalize adult-use cannabis, has taken a permissive approach to hemp-derived products while maintaining robust oversight of its licensed cannabis market. The state allows hemp-derived delta-8 THC and similar products to be sold outside the licensed cannabis system, but requires that all consumable hemp products be tested and labeled according to standards comparable to those for marijuana products. Colorado's Marijuana Enforcement Division and Department of Agriculture coordinate oversight to ensure consistent consumer protection.

Florida

Florida operates a medical cannabis program serving over 800,000 patients, making it one of the largest medical markets in the country. The state banned delta-8 THC and other intoxicating hemp-derived cannabinoids in 2023 through legislation that explicitly excludes such products from the hemp definition. Florida law now requires that any product containing THC above trace amounts be sold only through licensed medical marijuana treatment centers. Possession limits for medical patients range from 2.5 ounces of smokable cannabis per 35 days to larger amounts of other formulations.

New York

New York legalized adult-use cannabis in 2021 and has taken an aggressive stance on hemp-derived intoxicating products. The state's Office of Cannabis Management issued emergency regulations in 2023 prohibiting the sale of any cannabinoid product intended for human consumption containing more than trace amounts of THC outside the licensed cannabis system. The regulations apply to delta-8 THC, delta-9 THC, and other cannabinoids, effectively requiring that all intoxicating products be sold through licensed dispensaries. Adult-use possession limits in New York allow up to three ounces of cannabis flower or 24 grams of concentrated cannabis.

Ohio

Ohio voters approved adult-use legalization in 2023, with sales beginning in 2024. The state explicitly addressed hemp-derived intoxicating products in its implementation legislation, prohibiting the sale of any hemp product containing more than 0.3% total THC (including all isomers) outside the licensed cannabis system. Ohio's Division of Cannabis Control regulates both medical and adult-use markets, with possession limits of 2.5 ounces for adult-use consumers and larger amounts for medical patients depending on their physician recommendation.

Market and Business Implications

The outcome of Texas's THC legal battle will determine the viability of hundreds of businesses and reshape a market worth over $600 million annually.

Licensed Dispensary Economics

Licensed medical cannabis dispensaries in Texas operate under a capital-intensive business model requiring vertical integration. Operators typically invest $20 million to $50 million in cultivation facilities, processing equipment, security systems, and retail buildouts. These businesses face ongoing compliance costs including mandatory testing (approximately $400 to $800 per batch), seed-to-sale tracking systems, security personnel, and extensive record-keeping requirements.

Licensed operators pay a $6,000 annual license fee to DSHS plus additional fees for inspections and modifications. More significantly, these businesses cannot deduct ordinary business expenses under Section 280E of the Internal Revenue Code, which prohibits tax deductions for businesses trafficking in controlled substances. This federal tax penalty can result in effective tax rates exceeding 70% of gross profit, making profitability challenging even with regulatory exclusivity.

Several licensed operators have reported that hemp-derived product competition has reduced their revenue by 20% to 35% since 2024, threatening the financial viability of their operations. If courts rule that hemp retailers may continue selling intoxicating products, some licensed dispensaries may struggle to justify their compliance costs and could exit the market or seek legislative relief.

Hemp Retail Market Dynamics

Hemp-derived THC products generated an estimated $500 million in Texas sales during 2025, distributed across approximately 3,000 retail locations. These retailers operate with minimal regulatory overhead, typically requiring only standard business licenses and sales tax permits. Products are sourced from out-of-state manufacturers and wholesalers, with wholesale pricing for delta-8 THC distillate ranging from $500 to $1,500 per kilogram depending on purity and volume.

Retail margins on hemp-derived products typically range from 100% to 300%, making the category highly profitable for convenience stores, smoke shops, and dedicated CBD retailers. A typical smoke shop might generate $10,000 to $30,000 monthly in hemp-derived THC sales, representing 30% to 50% of total revenue. If courts prohibit these sales, thousands of small businesses would face significant revenue loss, and many could close entirely.

Wholesale and Manufacturing Impact

Texas hosts a growing hemp processing industry, with over 200 licensed processors converting raw hemp biomass into distillates, isolates, and finished products. These processors source hemp from in-state growers and out-of-state suppliers, with Texas hemp cultivation expanding to over 15,000 acres in 2025. The processing sector employs an estimated 2,000 workers and generates approximately $150 million in annual economic activity.

If hemp-derived intoxicating products are prohibited, processors would need to pivot to non-intoxicating products like CBD or exit the market. Some processors have already begun diversifying into other hemp derivatives like CBG and CBN in anticipation of potential regulatory restrictions. The impact would extend to hemp farmers, who have invested in cultivation infrastructure based on demand for high-cannabinoid hemp varieties.

Investment and Capital Markets

The regulatory uncertainty has chilled investment in Texas cannabis businesses. Licensed dispensaries have struggled to raise expansion capital given the unclear competitive landscape, while hemp businesses face difficulty accessing banking and payment processing due to federal ambiguity about the legality of intoxicating hemp products. Several multi-state operators (MSOs) have delayed plans to enter the Texas market pending resolution of the legal battle.

Private equity and venture capital firms have largely avoided Texas cannabis investments, preferring states with clearer regulatory frameworks. The few investors active in the space have demanded significant risk premiums, with some equity deals valuing licensed dispensaries at just 2x to 3x EBITDA compared to 6x to 8x multiples in mature markets like Colorado and California.

Tax Revenue Implications

Texas collects sales tax on both licensed medical cannabis and hemp-derived products at the standard 6.25% rate, plus local sales taxes. However, licensed dispensaries pay significantly higher fees and could potentially be subject to additional excise taxes if the legislature expands the medical program or authorizes adult-use sales. The state collected an estimated $40 million in sales tax from hemp-derived cannabinoid products in 2025, revenue that could disappear if courts prohibit these sales.

Some lawmakers have proposed creating a regulatory framework for hemp-derived products that would impose testing requirements, licensing fees, and excise taxes comparable to those in the medical program. Such an approach could generate tens of millions in new state revenue while addressing safety concerns, though it would likely reduce the profitability of hemp retail operations.

What Experts Say

Legal scholars, industry analysts, and policy experts offer divergent views on the likely outcome and optimal resolution of the Texas THC legal battle.

According to cannabis attorney Robert Mikos, a professor at Vanderbilt Law School who specializes in federalism and drug policy, Texas faces a fundamental conflict between its hemp and medical cannabis statutes that the legislature must resolve. Mikos has noted in published research that the 2018 Farm Bill created similar conflicts in multiple states, and courts have generally been reluctant to read implied prohibitions into hemp legalization statutes. He suggests that Texas courts may find that the legislature intended to legalize hemp derivatives unless explicitly prohibited, placing the burden on lawmakers to clarify their intent.

Industry analyst Bethany Gomez, managing director at Brightfield Group, has tracked the economic impact of hemp-derived cannabinoid markets across the United States. According to Brightfield's market research, states that have restricted hemp-derived intoxicating products have seen those sales shift to neighboring states or to illicit markets rather than to licensed dispensaries. Gomez has stated that the price differential between licensed medical cannabis and hemp-derived products is too large for most consumers to justify, suggesting that prohibiting hemp sales may not substantially benefit licensed operators.

Medical cannabis physician Dr. Joseph Cohen, who has certified over 5,000 patients for the Texas Compassionate Use Program, has expressed concern about the lack of quality control in hemp-derived products. According to Cohen, patients who purchase hemp products from unlicensed retailers face risks including inaccurate labeling, contamination with pesticides or heavy metals, and inconsistent potency. He has advocated for extending medical-grade testing and labeling requirements to all THC products regardless of source, rather than prohibiting hemp sales entirely.

Former Texas state representative Joe Moody, who authored the 2019 hemp legalization bill, has stated publicly that the legislature intended to broadly legalize hemp and its derivatives, not to create a narrow exception for non-intoxicating products only. According to Moody, lawmakers understood that hemp could be processed into various cannabinoids and deliberately chose permissive language to allow the industry to develop. He has suggested that attempts to restrict hemp-derived products contradict the original legislative intent.

Policy analyst John Hudak at the Brookings Institution has examined state cannabis regulatory frameworks nationwide and identified Texas as an example of the challenges created by overlapping federal and state hemp and marijuana laws. According to Hudak's analysis, states that have successfully managed this tension have done so through explicit legislative action that clearly delineates which products fall under cannabis regulation versus hemp regulation, rather than relying on administrative interpretations or judicial decisions.

Texas Department of Agriculture Commissioner Sid Miller has publicly supported hemp farmers and processors, stating that agriculture is a critical economic driver for rural Texas and that hemp represents an important crop diversification opportunity. Miller has argued that restricting hemp-derived products would harm Texas farmers and processors while benefiting out-of-state cannabis companies that dominate the licensed dispensary market.

Patient advocate Jax Finkel, executive director of the Texas Cannabis Collective, has emphasized that the legal battle ultimately affects patient access and affordability. According to Finkel, licensed medical cannabis products cost two to three times more than comparable hemp-derived products, creating affordability barriers for patients on fixed incomes. Finkel has called for expanding the Compassionate Use Program to include adult-use sales, which would create a regulated market accessible to all consumers while maintaining quality standards.

What's Next

The Texas THC legal battle will likely be resolved through a combination of judicial decisions and legislative action over the next 12 to 18 months.

Immediate Legal Timeline

The Travis County District Court cases filed by licensed dispensaries and hemp retailers are currently in discovery, with both sides exchanging documents and taking depositions. The court has scheduled a hearing on the dispensaries' motion for preliminary injunction for November 2026, which could result in a temporary order prohibiting hemp retailers from selling intoxicating products pending final resolution of the case. A ruling on the preliminary injunction is expected by December 2026.

If the court grants a preliminary injunction, hemp retailers would likely appeal to the Third Court of Appeals, potentially extending the legal uncertainty into 2027. Alternatively, if the court denies the injunction, licensed dispensaries may seek expedited appellate review. Legal experts anticipate that regardless of the trial court outcome, the losing party will appeal, meaning the case could ultimately reach the Texas Supreme Court.

Legislative Prospects (2027 Session)

The Texas Legislature convenes in regular session in January 2027, providing an opportunity for lawmakers to address the regulatory conflict through legislation. Multiple bills are expected to be filed, ranging from explicit bans on hemp-derived intoxicating products to comprehensive regulatory frameworks that would license and tax hemp retailers similarly to medical dispensaries.

Key legislators to watch include Senator Charles Schwertner, chair of the Senate Health and Human Services Committee, and Representative Stephanie Klick, chair of the House Public Health Committee. Both have expressed concern about unregulated THC products but have not committed to specific legislative approaches. The outcome will likely depend on lobbying efforts by licensed dispensaries, hemp retailers, agricultural interests, and patient advocacy groups.

Political observers note that Texas's conservative political culture generally favors free-market solutions and agricultural interests, which could benefit hemp retailers. However, concerns about youth access and public safety may drive support for tighter restrictions. The legislature could also choose to punt the issue again, allowing the courts to resolve the conflict.

Regulatory Scenarios

Several regulatory outcomes are possible depending on legislative and judicial action. In a restrictive scenario, courts or the legislature could prohibit all hemp-derived intoxicating products, channeling THC sales exclusively through licensed Compassionate Use Program dispensaries. This would